Bio-Solutions Corp.
OTC Bulletin Board : BISU

Bio-Solutions Corp.

July 10, 2009 09:46 ET

CORRECTION FROM SOURCE: Bio-Solutions Corp. Announces the Fast Marketing of a Second Organic Product to Counter Malaria

A correction from source is being issued with respect to the release sent out this morning at 07:00 am EDT. Please note that the fifth paragraph (Bio-Solutions Corp is a biotechnology company...) was not part of the press release and should be disregarded. The corrected version follows.

MONTREAL, CANADA--(Marketwire - July 10, 2009) - Bio-Solutions Corp. (OTCBB:BISU) will market new and very effective organic product to counter Malaria; GreenEx™. Malaria is the forefront of priorities for the World Health Organization. GreenEx™ is an organic insecticide available in solid or liquid form which neutralizes and eradicates up to 98% of the larvae, within only 24 hours. Malaria is the most dangerous disease transmissible by mosquitoes that we know of.

Each year, over 250 million people are infected and more than one million children under the age of five years die by cause of Malaria. "This organic product can be as useful in veterinary care as for human car; Bio-Solutions will advocate a specialized market strategy for GreenEx™. We will offer this product as a viable alternative to the countries dissatisfied of the service offered by the multinationals. In certain cases, the demands in services and products are too small to interest these large corporations, which is not our case" indicated Dr. Gilles Chaumillon PhD/MBA, CEO of Bio-Solutions Corp.

The Malaria related market represents several hundreds of million dollars in all the forms of products used against this disease. Bio-Solutions thus integrates in its portfolio, a product representing a large revenue potential. Malaria is an endemic disease in the tropical zones of the Americas, Asia, and most regions of Africa. However, Sub-Saharan Africa accounts for 85% to 90% of deaths (mostly children under the age of five years and pregnant women).

"We will propel the marketing of this product by the valorization of our international network and we will be able to quickly generate income for our company", indicated Dr. Gilles Chaumillom. "Bio-Solutions Corp can offer turn-key services to the countries affected by these difficult problems or to work out in partnership for swift strategic interventions with these countries at the scientific and business levels", added Dr. Gilles Chaumillon.

For more information on Bio-Solutions Corp. and its products, please visit the company's website at

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Bio-Solutions' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of studies, the ability of the Company to take advantage of business opportunities in the biotechnology industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements and disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except if we are requested by a governmental authority or applicable law.

Contact Information

  • Investor & Public Relations:
    ONZ Communications
    Selam Tewolde